Coherus Oncology Q3 sales miss estimates, LOQTORZI revenue up 12%

Coherus Oncology

06/11/2025 22:36

Overview

Coherus Q3 2025 sales miss analysts' expectations, adjusted net loss narrows less than expected

LOQTORZI net revenue rises 12% over Q2 2025, driven by higher patient demand

Company expands CHS-114 clinical program to include colorectal cancer

Outlook

Coherus expects multiple data readouts from ongoing studies throughout 2026

Company is expanding CHS-114 program to include colorectal cancer

Coherus plans to combine LOQTORZI with internal candidates for new indications

Result Drivers

LOQTORZI DEMAND - Higher patient demand and increased treatment duration drove a 12% increase in LOQTORZI net revenue over Q2 2025

NCCN GUIDELINES - Revised NCCN guidelines granting LOQTORZI preferred status drive demand growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Miss
$11.57 mln
$13.41 mln (5 Analysts)
Q3 Adjusted Net Income
Miss
-$38.90 mln
-$33.54 mln (5 Analysts)
Q3 Net Income
-$35.53 mln
Q3 Operating Income
-$44.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Coherus Oncology Inc is $6.00, about 73.9% above its November 5 closing price of $1.57

Press Release: ID:nGNX5xJZLw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)